Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600332's EV-to-FCF is ranked worse than 94.44% of 72
companies
in the Medical Distribution industry
Industry Median: 17.15
vs SHSE:600332: 200.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's PE Ratio (TTM) for today is calculated as:
Guangzhou Baiyunshan Pharmaceutical Holdings Co's share price for today is ¥21.59.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.812.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-FCF Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-FCF Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co EV-to-FCF vs Medical Distribution Industry
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Enterprise Value is ¥41,756 Mil.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥209 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) has a EV-to-FCF of 199.69 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 1020% above median its historical median of 17.83. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #68 out of 72 companies in the Medical Distribution industry, placing it in the top 94.4%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-FCF too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-FCF of 199.69 is 1020% above median its 10-year median of 17.83. The Medical Distribution industry median EV-to-FCF is 17.15. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 199.69 is 1064.4% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #68 out of 72 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's EV-to-FCF compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #68 out of 72 companies for EV-to-FCF. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. The industry median EV-to-FCF is 17.15. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 199.69 is 1064.4% above this benchmark. While the company's 10-year median is 17.83 vs. the industry median of 17.15, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.15, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-FCF of 199.69 is 1064.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current EV-to-FCF is 199.69, which is 1020% above median its own 10-year median of 17.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.48, compared to a current price of ¥21.59 — trading 26.8% below its estimated fair value. The current EV-to-FCF is 199.69, which is 1020% above median its 10-year median of 17.83 and 1064.4% above the Medical Distribution industry median of 17.15. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332), the current EV-to-FCF is 199.69 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of ¥21.59 is trading 26.8% below its estimated GF Value™ of ¥29.48.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for SHSE:600332:
EV-to-FCF: 199.69 (1020% above median its 10-year median of 17.83)
GF Value™: ¥29.48 vs. price of ¥21.59 (26.8% below fair value)
Industry Position: 1064.4% above the Medical Distribution median (#68 of 72)
No single metric tells the full story. See the SHSE:600332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
71GF Score
Get the complete analysis for SHSE:600332
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600332 has been successfully added to your 
